Effect of AC2993 (synthetic exendin-4) - administered alone or in combination with daclizumab - on islet function in patients with type I diabetes.
Phase of Trial: Phase II
Latest Information Update: 25 Jul 2014
At a glance
- Drugs Exenatide (Primary) ; Daclizumab
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Bristol-Myers Squibb
- 07 Jun 2017 Biomarkers information updated
- 05 Jan 2010 Actual number of patients (47) added as reported by ClinicalTrials.gov.
- 03 Jan 2009 Actual start date changed from 8 Jul 2003 to 1 Jul 2003 as reported by ClinicalTrials.gov.